Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 trial of atebimetinib (IMM-1-104) in combination with olomorasib (LY3537982) in patients with locally advanced or metastatic KRAS G12c-mutant progressive non-small cell lung cancer (NSCLC)

Next Previous
Trial Profile

A phase 2 trial of atebimetinib (IMM-1-104) in combination with olomorasib (LY3537982) in patients with locally advanced or metastatic KRAS G12c-mutant progressive non-small cell lung cancer (NSCLC)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 17 Oct 2025 New trial record
  • 25 Aug 2025 According to an Immuneering media release, the company announced a clinical supply agreement with Eli Lilly and Company for olomorasib being studied in combination with atebimetinib (IMM-1-104), in this planned phase 2 trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top